. Author manuscript; available in PMC: 2012 Apr 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e122–e128. doi: 10.1097/QAI.0b013e31820a7f2f

Table 2. Summary of HIV-exposed and HIV-infected infant tracing from antenatal clinic to pediatric ART Clinic, 2004-2008.

Women HIV antibody tested	101,251
HIV-infected women, n/N (%)	14,669/101,251 (14.5%)
HIV-infected women receiving any PMTCT prophylaxis^†	14,579/14,669 (99.2%)
ART (stavudine/lamivudine/nevirapine)	1,284/14,669 (8.8%)
Single dose NVP	13,295/14,669 (90.6%)
HIV-exposed infants receiving single dose NVP^†	6,930/14,669 (47.2%)
Infants HIV DNA PCR tested, n/N (%)	7,875/14,669 (53.7%)
HIV-infected infants, n/N (%)	1,084/7,875 (13.8%)
HIV-infected infants traced to an ART clinic, n/N (%)	320/1,084 (29.5%)
HIV-infected infants traced to the Baylor COE, n/N (%)	202/320 (63.1%)

ART, antiretroviral; DNA, Deoxyribonucleic nucleic acid; PCR, polymerase chain reaction, COE, Center of Excellence

^†

Received at ANC clinic, ingestion not verified.